Deutsche Bank analyst Emmanuel Papadakis maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of ...

In a report released today, Emily Field from Barclays maintained a Hold rating on GlaxoSmithKline (GSK – Research Report), with a price target ...

Want to brand your business without breaking the bank? The best free logo maker will be an essential tool in your marketing kit - and after testing these completely free logo designers ...

We've been getting creative with the best logo makers for branding your business online. It's difficult to understate the importance of good logo design - it's the quickest way for customers and ...

GSK’s share price has been pressured recently from several negative events, but this may leave a bargain to be had. I’ve investigated whether this is the case. When investing, your capital is ...

Of course, some criticize these modern logos as being copy-and-paste, minimalist and unoriginal. Those yearn to return to the unique logos of the 1990s and early 2000s, where the NFL used elements ...

Walmart steel cage match (although we would totally watch). Instead, Walmart gave its logo a makeover fit for modern times—at least that was the idea. But people, well, they have feelings.

Both assets are poised to enter registrational studies under accelerated approval pathways, according to Jefferies. GSK to Stay Out of Obesity—but not GLP-1s At JPM25 on Monday, GSK Chief Scientific ...

Walmart announced on Monday that it had unveiled a new logo, part of "a comprehensive brand refresh." The U.S.-based retailer boasted in a news release that the new look — its first change ...

Brand New Membership Level: Benzinga Trade Alerts GSK plc GSK expects strong momentum in the specialty business segment to continue with growth from existing assets. At the JPMorgan Healthcare ...

Following GSK’s deal-heavy end to 2024, Chief Scientific Officer Tony Wood, Ph.D., doesn’t expect the trend to let up in the new year, zeroing in on partnerships that can expand knowledge ...

Eli Lilly made a $2.5 billion deal for a breast cancer drug; GSK reached a $1 billion-plus deal for IDRx. The announcements suggest a potential rebound in M&A deals in the healthcare sector for 2025.